Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant p53 Depletion by Novel Inhibitors for HSP40/J-Domain Proteins Derived from the Natural Compound Plumbagin

29 Aug 2022

Abstract excerpt

Accumulation of missense mutant p53 (mutp53) in cancers promotes malignant progression. DNAJA1, a member of HSP40 (also known as J-domain proteins: JDPs), is shown to prevent misfolded or conformational mutp53 from proteasomal degradation. Given frequent addiction of cancers to oncogenic mutp53, depleting mutp53 by DNAJA1 inhibition is a promising approach for cancer therapy. However, there is no clinically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Synthase and ATPases Research
Share to Bioactive Compounds and Antitumor Agents
Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36077724
DOI: 10.3390/cancers14174187

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant p53 Depletion by Novel Inhibitors for HSP40/J-Domain Proteins Derived from the Natural Compound PlumbaginPMID 36077724Read ↗

Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220CSemantic proximity Read ↗

Anticancer therapeutic strategies for targeting mutant p53-Y220CSemantic proximity Read ↗

DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.Semantic proximity Read ↗

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.Semantic proximity Read ↗

A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability.Semantic proximity Read ↗

DARPins as pan-reactivators of temperature-sensitive p53 cancer mutants.Semantic proximity Read ↗

Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in DevelopmentSemantic proximity Read ↗

In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity.Semantic proximity Read ↗

Flavonoids as potential reactivators of structural mutation p53Y220C by computational and cell-based studies.Semantic proximity Read ↗

An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer.Semantic proximity Read ↗

Small molecules that targeting p53 Y220C protein: mechanisms, structures, and clinical advances in anti-tumor therapySemantic proximity Read ↗

Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.